Clinical impact of sexual dimorphism in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
HCC
NAFLD/NASH
acute-on-chronic liver failure
chronic kidney disease
liver disease
liver transplantation
sex dimorphism
Journal
Liver international : official journal of the International Association for the Study of the Liver
ISSN: 1478-3231
Titre abrégé: Liver Int
Pays: United States
ID NLM: 101160857
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
revised:
05
05
2021
received:
08
12
2020
accepted:
06
05
2021
pubmed:
14
5
2021
medline:
3
8
2021
entrez:
13
5
2021
Statut:
ppublish
Résumé
NAFLD/NASH is a sex-dimorphic disease, with a general higher prevalence in men. Women are at reduced risk of NAFLD compared to men in fertile age, whereas after menopause women have a comparable prevalence of NAFLD as men. Indeed, sexual category, sex hormones and gender habits interact with numerous NAFLD factors including cytokines, stress and environmental factors and alter the risk profiles and phenotypes of NAFLD. In the present review, we summarized the last findings about the influence of sex on epidemiology, pathogenesis, progression in cirrhosis, indication for liver transplantation and alternative therapies, including lifestyle modification and pharmacological strategies. We are confident that an appropriate consideration of sex, age, hormonal status and sociocultural gender differences will lead to a better understanding of sex differences in NAFLD risk, therapeutic targets and treatment responses and will aid in achieving sex-specific personalized therapies.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1713-1733Informations de copyright
© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Younossi ZM, Marchesini G, Pinto-Cortez H, et al. Epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: implications for liver transplantation. Transplantation. 2019;103:22-27.
Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15:11-20.
Lonardo A, Nascimbeni F, Ballestri S, et al. Sex differences in nonalcoholic fatty liver disease: state of the art and identification of research gaps. Hepatology. 2019;70:1457-1469.
Miller VM, Rocca WA, Faubion SS. Sex differences research, precision medicine, and the future of women's health. J Womens Health (Larchmt). 2015;24:969-971.
Mauvais-Jarvis F, Bairey Merz N, Barnes PJ, et al. Sex and gender: modifiers of health, disease, and medicine. Lancet. 2020;396:565-582.
Craft BB, Carroll HA, Lustyk MK. Gender differences in exercise habits and quality of life reports: assessing the moderating effects of reasons for exercise. Int J Lib Arts Soc Sci. 2014;2:65-76.
Ricci G, Canducci E, Guida A, et al. The gender-related differences of nutrient intakes in a group of Italian obese patients display the ongoing transition from Mediterranean to western dietary patterns. Obes Surg. 2014;24:965-967.
Yu BCY, Kwok D, Wong VWS. Magnitude of nonalcoholic fatty liver disease: eastern perspective. J Clin Exp Hepatol. 2019;9:491-496.
Samji NS, Verma R, Satapathy SK. Magnitude of nonalcoholic fatty liver disease: western perspective. J Clin Exp Hepatol. 2019;9:497-505.
Finucane MM, Stevens GA, Cowan MJ, et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet. 2011;377:557-567.
Kojima S-I, Watanabe N, Numata M, et al. Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical background. J Gastroenterol. 2003;38:954-961.
Hamaguchi M, Kojima T, Takeda N, et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med. 2005;143:722-728.
Suzuki A, Angulo P, Lymp J, et al. Chronological development of elevated aminotransferases in a nonalcoholic population. Hepatology. 2005;41:64-71.
Tsuneto A, Hida A, Sera N, et al. Fatty liver incidence and predictive variables. Hypertens Res. 2010;33:638-643.
Hamaguchi M, Kojima T, Ohbora A, et al. Aging is a risk factor of nonalcoholic fatty liver disease in premenopausal women. World J Gastroenterol. 2012;18:237-243.
Zhou YJ, Li YY, Nie YQ, et al. Natural course of nonalcoholic fatty liver disease in southern China: a prospective cohort study. Journal of Digestive Diseases. 2012;13:153-160.
Zelber-Sagi S, Lotan R, Shlomai A, et al. Predictors for incidence and remission of NAFLD in the general population during a seven-year prospective follow-up. J Hepatol. 2012;56:1145-1151.
Sung K-C, Kim B-S, Cho Y-K, et al. Predicting incident fatty liver using simple cardio-metabolic risk factors at baseline. BMC Gastroenterol. 2012;12.
Xu C, Yu C, Ma H, et al. Prevalence and risk factors for the development of nonalcoholic fatty liver disease in a nonobese Chinese population: the zhejiang zhenhai study. Am J Gastroenterol. 2013;108:1299-1304.
Wong V-S, Wong G-H, Yeung D-W, et al. Incidence of non-alcoholic fatty liver disease in Hong Kong: a population study with paired proton-magnetic resonance spectroscopy. J Hepatol. 2015;62:182-189.
Yun KE, Nam GE, Lim J, et al. Waist gain is associated with a higher incidence of nonalcoholic fatty liver disease in Korean adults: a cohort study. PLoS One. 2016;11:e0158710.
Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73-84.
James SL, Abate D, Abate KH, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the global burden of disease study 2017. Lancet. 2018;392:1789-1858.
Bellentani S, Scaglioni F, Marino M, et al. Epidemiology of non-alcoholic fatty liver disease. Dig Dis. 2010;28:155-161.
Bedogni G, Miglioli L, Masutti F, et al. Prevalence of and risk factors for nonalcoholic fatty liver disease: the dionysos nutrition and liver study. Hepatology. 2005;42:44-52.
Bellentani S, Pozzato G, Saccoccio G, et al. Clinical course and risk factors of hepatitis C virus related liver disease in the general population: report from the dionysos study. Gut. 1999;44:874-880.
Lonardo A, Bellentani S, Argo CK, et al. Epidemiological modifiers of non-alcoholic fatty liver disease: focus on high-risk groups. Dig Liver Dis. 2015;47:997-1006.
Younossi ZM, Golabi P, de Avila L, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol. 2019;71:793-801.
Nobili V, Alisi A, Valenti L, et al. NAFLD in children: new genes, new diagnostic modalities and new drugs. Nat Rev Gastroenterol Hepatol. 2019;16:517-530.
Abeysekera KWM, Fernandes GS, Hammerton G, et al. Prevalence of steatosis and fibrosis in young adults in the UK: a population-based study. The lancet Gastroenterology & hepatology. 2020;5:295-305.
Selvakumar PKC, Kabbany MN, Rifai G, et al. Prevalence of nonalcoholic steatohepatitis and advanced fibrosis in adolescents with nonalcoholic fatty liver disease in the United States. Hepatology. 2016;64:106A.
Ruhl CE, Everhart JE. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology. 2003;124:71-79.
Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol. 2003;98:960-967.
Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40:1387-1395.
Ioannou GN, Boyko EJ, Lee SP. The prevalence and predictors of elevated serum aminotransferase activity in the United States in 1999-2002. Am J Gastroenterol. 2006;101:76-82.
Lazo M, Hernaez R, Eberhardt MS, et al. Prevalence of nonalcoholic fatty liver disease in the United States: the third national health and nutrition examination survey, 1988-1994. Am J Epidemiol. 2013;178:38-45.
Schneider ALC, Lazo M, Selvin E, et al. Racial differences in nonalcoholic fatty liver disease in the US population. Obesity. 2014;22:292-299.
Ballestri S, Nascimbeni F, Baldelli E, et al. NAFLD as a sexual dimorphic disease: role of gender and reproductive status in the development and progression of nonalcoholic fatty liver disease and inherent cardiovascular risk. Adv Ther. 2017;34:1291-1326.
Fan J-G, Zhu J, Li X-J, et al. Prevalence of and risk factors for fatty liver in a general population of Shanghai China. J Hepatol. 2005;43:508-514.
Eguchi Y, Hyogo H, Ono M, et al. Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study. J Gastroenterol. 2012;47:586-595.
Yang JD, Abdelmalek MF, Pang H, et al. Gender and menopause impact severity of fibrosis among patients with nonalcoholic steatohepatitis. Hepatology. 2014;59:1406-1414.
Tobari M, Hashimoto E. Characteristic features of nonalcoholic fatty liver disease in japan with a focus on the roles of age, sex and body mass index. Gut Liv. 2020;14:537-545.
Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology. 2002;122:1649-1657.
McKenzie J, Fisher BM, Jaap AJ, et al. Effects of HRT on liver enzyme levels in women with type 2 diabetes: a randomized placebo-controlled trial. Clin Endocrinol (Oxf). 2006;65:40-44.
Ayonrinde OT, Olynyk JK, Beilin LJ, et al. Gender-specific differences in adipose distribution and adipocytokines influence adolescent nonalcoholic fatty liver disease. Hepatology. 2011;53:800-809.
Solga S, Alkhuraishe AR, Clark JM, et al. Dietary composition and nonalcoholic fatty liver disease. Dig Dis Sci. 2004;49:1578-1583.
Zelber-Sagi S, Nitzan-Kaluski D, Goldsmith R, et al. Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): a population based study. J Hepatol. 2007;47:711-717.
Cortez-Pinto H, Jesus L, Barros H, et al. How different is the dietary pattern in non-alcoholic steatohepatitis patients? Clin Nutr. 2006;25:816-823.
Da Silva HE, Teterina A, Comelli EM, et al. Nonalcoholic fatty liver disease is associated with dysbiosis independent of body mass index and insulin resistance. Sci Rep. 2018;8:1466.
Wehmeyer MH, Zyriax B-C, Jagemann B, et al. Nonalcoholic fatty liver disease is associated with excessive calorie intake rather than a distinctive dietary pattern. Med (Baltimore). 2016;95:e3887.
Han JM, Jo AN, Lee SM, et al. Associations between intakes of individual nutrients or whole food groups and non-alcoholic fatty liver disease among Korean adults. J Gastroenterol Hepatol. 2014;29:1265-1272.
Hörist-Kollmann S, Strametz-Juranek J. Female dietary patterns and the pathogenesis of NAFLD. Gender and the Genome. 2018;2:49-55.
De Irala-Estévez J, Groth M, Johansson L, et al. A systematic review of socio-economic differences in food habits in Europe: consumption of fruit and vegetables. Eur J Clin Nutr. 2000;54:706-714.
Noureddin M, Zelber-Sagi S, Wilkens LR, et al. Diet associations with nonalcoholic fatty liver disease in an ethnically diverse population: the multiethnic cohort. Hepatol. 2020;71(6):1940-1952.
Hyer MM, Dyer SK, Kloster A, et al. Sex modifies the consequences of extended fructose consumption on liver health, motor function, and physiological damage in rats. Am J Physiol Regul Integr Comp Physiol. 2019;317:R903-R911.
Sherriff JL, O'Sullivan TA, Properzi C, et al. Choline, its potential role in nonalcoholic fatty liver disease, and the case for human and bacterial genes. Advances in Nutrition. 2016;7:5-13.
Guerrerio AL, Colvin RM, Schwartz AK, et al. Choline intake in a large cohort of patients with nonalcoholic fatty liver disease. Am J Clin Nutr. 2012;95:892-900.
Resseguie M, Song J, Niculescu MD, et al. Phosphatidylethanolamine N-methyltransferase (PEMT) gene expression is induced by estrogen in human and mouse primary hepatocytes. Faseb j. 2007;21:2622-2632.
Åberg F, Helenius-Hietala J, Puukka P, et al. Interaction between alcohol consumption and metabolic syndrome in predicting severe liver disease in the general population. Hepatology. 2018;67:2141-2149.
Moshage H. Alcoholic liver disease: a matter of hormones? J Hepatol. 2001;35:130-133.
Esteban JPG, Rein LE, Szabo A, et al. Not just what, but also when you eat: analyzing the impact of meal timing patterns on non-alcoholic fatty liver disease. Hepatology. 2016;64:17A-A18.
Dig Liver Dis. AISF position paper on nonalcoholic fatty liver disease (NAFLD): updates and future directions. 2017;49:471-483.
Marra F, Lotersztajn S. Pathophysiology of NASH: perspectives for a targeted treatment. Curr Pharm Des. 2013;19:5250-5269.
Marra F, Svegliati-Baroni G. Lipotoxicity and the gut-liver axis in NASH pathogenesis. J Hepatol. 2018;68:280-295.
Delogu W, Caligiuri A, Provenzano A, et al. Myostatin regulates the fibrogenic phenotype of hepatic stellate cells via c-jun N-terminal kinase activation. Dig Liver Dis. 2019;51:1400-1408.
Beaudry KM, Devries MC. Sex-based differences in hepatic and skeletal muscle triglyceride storage and metabolism (1). Appl Physiol Nutr Metab. 2019;44:805-813.
Leibel RL, Edens NK, Fried SK. Physiologic basis for the control of body fat distribution in humans. Annu Rev Nutr. 1989;9:417-443.
Park Y-M, Pereira RI, Erickson CB, et al. Estradiol-mediated improvements in adipose tissue insulin sensitivity are related to the balance of adipose tissue estrogen receptor α and β in postmenopausal women. PLoS One. 2017;12:e0176446.
Escobar-Morreale HF, Alvarez-Blasco F, Botella-Carretero JI, et al. The striking similarities in the metabolic associations of female androgen excess and male androgen deficiency. Hum Reprod. 2014;29:2083-2091.
Palmisano BT, Zhu L, Stafford JM. Role of estrogens in the regulation of liver lipid metabolism. Adv Exp Med Biol. 2017;1043:227-256.
Low WS, Cornfield T, Charlton CA, et al. Sex differences in hepatic de novo lipogenesis with acute fructose feeding. Nutrients. 2018;10(9):1263.
Couchepin C, Lê KA, Bortolotti M, et al. Markedly blunted metabolic effects of fructose in healthy young female subjects compared with male subjects. Diabetes Care. 2008;31:1254-1256.
Tran C, Jacot-Descombes D, Lecoultre V, et al. Sex differences in lipid and glucose kinetics after ingestion of an acute oral fructose load. Br J Nutr. 2010;104:1139-1147.
González-Granillo M, Helguero LA, Alves E, et al. Sex-specific lipid molecular signatures in obesity-associated metabolic dysfunctions revealed by lipidomic characterization in ob/ob mouse. Biol Sex Differ. 2019;10:11.
Høeg LD, Sjøberg KA, Lundsgaard A-M, et al. Adiponectin concentration is associated with muscle insulin sensitivity, AMPK phosphorylation, and ceramide content in skeletal muscles of men but not women. J Appl Physiol. 1985;2013(114):592-601.
Anderson LJ, Liu H, Garcia JM. Sex differences in muscle wasting. Adv Exp Med Biol. 2017;1043:153-197.
Sørensen MB, Rosenfalck AM, Højgaard L, et al. Obesity and sarcopenia after menopause are reversed by sex hormone replacement therapy. Obes Res. 2001;9:622-626.
Marra F, Tacke F. Roles for chemokines in liver disease. Gastroenterology. 2014;147:577-94.e1.
Ministrini S, Montecucco F, Sahebkar A, et al. Macrophages in the pathophysiology of NAFLD: the role of sex differences. Eur J Clin Invest. 2020;50:e13236.
Becerra-Díaz M, Strickland AB, Keselman A, et al. Androgen and Androgen Receptor as Enhancers of M2 Macrophage Polarization in Allergic Lung Inflammation. J Immunol. 2018;201:2923-2933.
Klein SL, Marriott I, Fish EN. Sex-based differences in immune function and responses to vaccination. Trans R Soc Trop Med Hyg. 2015;109:9-15.
Marra F, Bertolani C. Adipokines in liver diseases. Hepatology. 2009;50:957-969.
Valencak TG, Osterrieder A, Schulz TJ. Sex matters: the effects of biological sex on adipose tissue biology and energy metabolism. Redox Biol. 2017;12:806-813.
Licinio J, Negrão AB, Mantzoros C, et al. Sex differences in circulating human leptin pulse amplitude: clinical implications. J Clin Endocrinol Metab. 1998;83:4140-4147.
Xu YXZ, Bassi G, Mishra S. Prohibitin: a prime candidate for a pleiotropic effector that mediates sex differences in obesity, insulin resistance, and metabolic dysregulation. Biol Sex Differ. 2019;10:25.
Suzuki Y, Ikeda K, Sakuma K, et al. Association between yogurt consumption and intestinal microbiota in healthy young adults differs by host gender. Front Microbiol. 2017;8:847.
Razavi AC, Potts KS, Kelly TN, et al. Sex, gut microbiome, and cardiovascular disease risk. Biol Sex Differ. 2019;10:29.
Santos-Marcos JA, Rangel-Zuñiga OA, Jimenez-Lucena R, et al. Influence of gender and menopausal status on gut microbiota. Maturitas. 2018;116:43-53.
Fu ZD, Csanaky IL, Klaassen CD. Gender-divergent profile of bile acid homeostasis during aging of mice. PLoS One. 2012;7:e32551.
Yatsuji S, Hashimoto E, Tobari M, et al. Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C. J Gastroenterol Hepatol. 2009;24:248-254.
Angulo P, Keach JC, Batts KP, et al. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology. 1999;30:1356-1362.
Axley P, Ahmed Z, Arora S, et al. NASH Is the most rapidly growing etiology for acute-on-chronic liver failure-related hospitalization and disease burden in the united states: a population-based study. Liver Transpl. 2019;25:695-705.
Doycheva I, Thuluvath PJ. Acute-on-chronic liver failure in liver transplant candidates with non-alcoholic steatohepatitis. Transl Gastroenterol Hepatol. 2020;5:38.
Kanwal F, Kramer JR, Mapakshi S, et al. Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease. Gastroenterology. 2018;155:1828-37.e2.
Ascha MS, Hanouneh IA, Lopez R, et al. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology. 2010;51:1972-1978.
Park JW, Chen M, Colombo M, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int. 2015;35:2155-2166.
Iyer JK, Kalra M, Kaul A, et al. Estrogen receptor expression in chronic hepatitis C and hepatocellular carcinoma pathogenesis. World J Gastroenterol. 2017;23:6802-6816.
Wu EM, Wong LL, Hernandez BY, et al. Gender differences in hepatocellular cancer: disparities in nonalcoholic fatty liver disease/steatohepatitis and liver transplantation. Hepatoma Res. 2018;4.
Simon TG, King LY, Chong DQ, et al. Diabetes, metabolic comorbidities, and risk of hepatocellular carcinoma: results from two prospective cohort studies. Hepatology. 2018;67:1797-1806.
Dyson J, Jaques B, Chattopadyhay D, et al. Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team. J Hepatol. 2014;60:110-117.
van Meer S, van Erpecum KJ, Sprengers D, et al. Hepatocellular carcinoma in cirrhotic versus noncirrhotic livers: results from a large cohort in the Netherlands. Eur J Gastroenterol Hepatol. 2016;28:352-359.
Mittal S, Sada YH, El-Serag HB, et al. Temporal trends of nonalcoholic fatty liver disease-related hepatocellular carcinoma in the veteran affairs population. Clin Gastroenterol Hepatol. 2015;13:594-601.
Reig M, Gambato M, Man NK, et al. Should patients with NAFLD/NASH be surveyed for HCC? Transplantation. 2019;103:39-44.
Kim G-A, Lee HC, Choe J, et al. Association between non-alcoholic fatty liver disease and cancer incidence rate. J Hepatol. 2018;68:140-146.
Yang N-B, Li G-X, Chu J-G, et al. Letter to the editors: consider more factors when studying risk of cirrhosis and hepatocellular cancer in NAFLD Patients. Hepatology. 2020;71(6):2172-2173.
Yasui K, Hashimoto E, Komorizono Y, et al. Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2011;9:428-33.quiz e50.
Buch SC, Kondragunta V, Branch RA, et al. Gender-based outcomes differences in unresectable hepatocellular carcinoma. Hepatol Int. 2008;2:95-101.
Vigano L, Conci S, Cescon M, et al. Liver resection for hepatocellular carcinoma in patients with metabolic syndrome: a multicenter matched analysis with HCV-related HCC. J Hepatol. 2015;63:93-101.
Pesapane F, Nezami N, Patella F, et al. New concepts in embolotherapy of HCC. Med Oncol. 2017;34:58.
Kim JY, Yoo EJ, Jang JW, et al. Hypofractionated radiotheapy using helical tomotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. Radiat Oncol. 2013;8:15.
Hocquelet A, Aubé C, Rode A, et al. Comparison of no-touch multi-bipolar vs. monopolar radiofrequency ablation for small HCC. J Hepatol. 2017;66:67-74.
Than NN, Ghazanfar A, Hodson J, et al. Comparing clinical presentations, treatments and outcomes of hepatocellular carcinoma due to hepatitis C and non-alcoholic fatty liver disease. QJM: Inter J Med. 2016;110:73-81.
Sangro B, Inarrairaegui M, Bilbao JI. Radioembolization for hepatocellular carcinoma. J Hepatol. 2012;56:464-473.
Phipps M, Livanos A, Guo A, et al. Gender matters: characteristics of hepatocellular carcinoma in women from a large, multicenter study in the United States. Am J Gastroenterol. 2020;115(9):1486-1495.
Sobotka L, Hinton A, Conteh L. Women receive more inpatient resections and ablations for hepatocellular carcinoma than men. World J Hepatol. 2017;9:1346-1351.
Cauble S, Abbas A, Balart L, et al. United States women receive more curative treatment for hepatocellular carcinoma than men. Dig Dis Sci. 2013;58:2817-2825.
Iqbal U, Perumpail B, Akhtar D, et al. The epidemiology, risk profiling and diagnostic challenges of nonalcoholic fatty liver disease. Med (Basel). 2019;6:14.
Wang X, Li J, Riaz DR, et al. Outcomes of liver transplantation for nonalcoholic steatohepatitis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2014;12(3):394-402.
Noureddin M, Vipani A, Bresee C, et al. NASH leading cause of liver transplant in women: updated analysis of indications for liver transplant and ethnic and gender variances. Am J Gastroenterol. 2018;113:1649-1659.
Holmer M, Melum E, Isoniemi H, et al. Nonalcoholic fatty liver disease is an increasing indication for liver transplantation in the Nordic countries. Liver Int. 2018;38:2082-2090.
Ferrarese A, Germani G, Gambato M, et al. Hepatitis C virus related cirrhosis decreased as indication to liver transplantation since the introduction of direct-acting antivirals: a single-center study. World J Gastroenterol. 2018;24:4403-4411.
Park CW, Tsai NT, Wong LL. Implications of worse renal dysfunction and medical comorbidities in patients with NASH undergoing liver transplant evaluation: impact on MELD and more. Clin Transplant. 2011;25:E606-E611.
Germani G, Zeni N, Zanetto A, et al. Influence of donor and recipient gender on liver transplantation outcomes in Europe. Liver International. 2020;40(8):1961-1971.
Loy VM, Joyce C, Bello S, et al. Gender disparities in liver transplant candidates with nonalcoholic steatohepatitis. Clin Transplant. 2018;32:e13297.
Targher G, Bertolini L, Rodella S, et al. Relationship between kidney function and liver histology in subjects with nonalcoholic steatohepatitis. Clin J Am Soc Nephrol. 2010;5:2166-2171.
Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med. 2003;349:931-940.
Burra P, Senzolo M, Masier A, et al. Factors influencing renal function after liver transplantation. results from the MOST, an international observational study. Dig Liver Dis. 2009;41:350-356.
Gill JS, Tonelli M, Mix CH, et al. The change in allograft function among long-term kidney transplant recipients. J Am Soc Nephrol. 2003;14:1636-1642.
Becchetti C, Zeni N, Ferrarese A, et al. Prevalence of de novo metabolic syndrome and its risk factors in a liver transplanted population: a prospective study. Dig Liver Dis. 2019;51:E174.
Saeed N, Glass L, Sharma P, et al. Incidence and risks for nonalcoholic fatty liver disease and steatohepatitis post-liver transplant: systematic review and meta-analysis. Transplantation. 2019;103:e345-e354.
Haldar D, Kern B, Hodson J, et al. Outcomes of liver transplantation for non-alcoholic steatohepatitis: a European liver transplant registry study. J Hepatol. 2019;71:313-322.
Do A, Kuszewski EJ, Langberg KA, et al. Incorporating weight loss medications into hepatology practice for nonalcoholic steatohepatitis. Hepatology. 2019;70:1443-1456.
Lazo M, Solga SF, Horska A, et al. Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes. Diabetes Care. 2010;33:2156.
Patel NS, Doycheva I, Peterson MR, et al. Effect of weight loss on magnetic resonance imaging estimation of liver fat and volume in patients with nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2015;13:561-8.e1.
Eckard C, Cole R, Lockwood J, et al. Prospective histopathologic evaluation of lifestyle modification in nonalcoholic fatty liver disease: a randomized trial. Therap Adv Gastroenterol. 2013;6:249-259.
J Hepatol. EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. 2016;64:1388-1402.
Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the american association for the study of liver diseases. Hepatology. 2018;67:328-357.
Kane AE, Sinclair DA, Mitchell JR, et al. Sex differences in the response to dietary restriction in rodents. Curr Opin Physiol. 2018;6:28-34.
Williams RL, Wood LG, Collins CE, et al. Effectiveness of weight loss interventions-is there a difference between men and women: a systematic review. Obes Rev. 2015;16:171-186.
Robertson C, Avenell A, Boachie C, et al. Should weight loss and maintenance programmes be designed differently for men? A systematic review of long-term randomised controlled trials presenting data for men and women: the ROMEO project. Obes Res Clin Pract. 2016;10:70-84.
Christensen P, Meinert Larsen T, Westerterp-Plantenga M, et al. Men and women respond differently to rapid weight loss: metabolic outcomes of a multi-centre intervention study after a low-energy diet in 2500 overweight, individuals with pre-diabetes (PREVIEW). Diabetes Obes Metab. 2018;20:2840-2851.
Lönnqvist F, Thörne A, Large V, et al. Sex differences in visceral fat lipolysis and metabolic complications of obesity. Arterioscler Thromb Vasc Biol. 1997;17:1472-1480.
Doucet E, St-Pierre S, Alméras N, et al. Reduction of visceral adipose tissue during weight loss. Eur J Clin Nutr. 2002;56:297-304.
Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. Gastroenterology. 2015;149:367-78.e5.quiz e14-5.
Kim D, Vazquez-Montesino LM, Li AA, et al. Inadequate physical activity and sedentary behavior are independent predictors of nonalcoholic fatty liver disease. Hepatology. 2020.
Henderson GC. Sexual dimorphism in the effects of exercise on metabolism of lipids to support resting metabolism. Front Endocrinol (Lausanne). 2014;5:162.
Lundsgaard AM, Kiens B. Gender differences in skeletal muscle substrate metabolism - molecular mechanisms and insulin sensitivity. Front Endocrinol (Lausanne). 2014;5:195.
Suzuki A, Abdelmalek MF. Nonalcoholic fatty liver disease in women. Womens Health (Lond). 2009;5:191-203.
Hashida R, Kawaguchi T, Bekki M, et al. Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: a systematic review. J Hepatol. 2017;66:142-152.
Barsalani R, Riesco E, Lavoie J-M, et al. Effect of exercise training and isoflavones on hepatic steatosis in overweight postmenopausal women. Climacteric. 2013;16:88-95.
Rezende REF, Duarte SMB, Stefano JT, et al. Randomized clinical trial: benefits of aerobic physical activity for 24 weeks in postmenopausal women with nonalcoholic fatty liver disease. Menopause. 2016;23:876-883.
Francque S, Vonghia L. Pharmacological treatment for non-alcoholic fatty liver disease. Adv Ther. 2019;36:1052-1074.
Yan H, Wu W, Chang X, et al. Gender differences in the efficacy of pioglitazone treatment in nonalcoholic fatty liver disease patients with abnormal glucose metabolism. biology of sex. Differences. 2021;12:1.
Pinkerton JV. Hormone therapy for postmenopausal women. N Engl J Med. 2020;382:446-455.
Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial. JAMA. 2002;288:321-333.
McKenzie J, Jaap AJ, Gallacher S, et al. Metabolic, inflammatory and haemostatic effects of a low-dose continuous combined HRT in women with type 2 diabetes: potentially safer with respect to vascular risk? Clin Endocrinol (Oxf). 2003;59:682-689.
Caligiuri A, Gentilini A, Marra F. Molecular pathogenesis of NASH. Int J Mol Sci. 2016;17:e1575.
Dalal PK, Agarwal M. Postmenopausal syndrome. Indian J psychiatry. 2015;57:S222-S232.
Dakin RS, Walker BR, Seckl JR, et al. Estrogens protect male mice from obesity complications and influence glucocorticoid metabolism. Int J Obes. 2015;39:1539-1547.
Ponnusamy S, Tran QT, Thiyagarajan T, et al. An estrogen receptor beta-selective agonist inhibits non-alcoholic steatohepatitis in preclinical models by regulating bile acid and xenobiotic receptors. Exp Biol Med (Maywood). 2017;242:606-616.
Wu J, Yao XY, Shi RX, et al. A potential link between polycystic ovary syndrome and non-alcoholic fatty liver disease: an update meta-analysis. Reprod Health. 2018;15:77.
Jones H, Sprung VS, Pugh CJA, et al. Polycystic ovary syndrome with hyperandrogenism is characterized by an increased risk of hepatic steatosis compared to nonhyperandrogenic pcos phenotypes and healthy controls, independent of obesity and insulin resistance. J Clin Endocrinol Metab. 2012;97:3709-3716.
Handelsman DJ, Sikaris K, Ly LP. Estimating age-specific trends in circulating testosterone and sex hormone-binding globulin in males and females across the lifespan. Ann Clin Biochem. 2016;53:377-384.
Sarkar MA, Suzuki A, Abdelmalek MF, et al. Testosterone is associated with nonalcoholic steatohepatitis and fibrosis in premenopausal women with NAFLD. Clin Gastroenterol Hepatol. 2020.
Park J-M, Lee HS, Oh J, et al. Serum testosterone level within normal range is positively associated with nonalcoholic fatty liver disease in premenopausal but not postmenopausal women. J Women's Health. 2019;28:1077-1082.
Sarkar M, Wellons M, Cedars MI, et al. Testosterone levels in pre-menopausal women are associated with nonalcoholic fatty liver disease in midlife. Am J Gastroenterol. 2017;112:755-762.
Polyzos SA, Kountouras J, Tsatsoulis A, et al. Sex steroids and sex hormone-binding globulin in postmenopausal women with nonalcoholic fatty liver disease. Horm-Int J Endocrino Meta. 2013;12:405-416.
Lazo M, Zeb I, Nasir K, et al. Association between endogenous sex hormones and liver fat in a multiethnic study of atherosclerosis. Clin Gastroenterol Hepatol. 2015;13(9):1686-1693.e2.
Polyzos SA, Kountouras J, Mantzoros CS, et al. Effects of combined low-dose spironolactone plus vitamin E vs vitamin E monotherapy on insulin resistance, non-invasive indices of steatosis and fibrosis, and adipokine levels in non-alcoholic fatty liver disease: a randomized controlled trial. Diabetes Obes Metab. 2017;19:1805-1809.
Sarkar M, Yates K, Suzuki A, et al. Low testosterone is associated with nonalcoholic steatohepatitis (NASH) and severity of NASH fibrosis in men with NAFLD. Clin Gastroenterol Hepatol. 2021;19(2):400-402.e2.
Jaruvongvanich V, Sanguankeo A, Riangwiwat T, et al. Testosterone, sex hormone-binding globulin and nonalcoholic fatty liver disease: a systematic review and meta-analysis. Ann Hepatol. 2017;16:382-394.
Younossi ZM, Ratziu V, Loomba R, et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2019;394:2184-2196.
Sanyal A, Lopez P, Lawitz E, et al. Tropifexor, a farnesoid X receptor agonist for the treatment of non-alcoholic steatohepatitis: Interim results based on baseline body mass index from first two parts of Phase 2b study FLIGHT-FXR. J Hepatol. 2019;70:E796-E797.
Lucas KJ, Lopez P, Lawitz E, et al. Tropifexor, a highly potent FXR agonist, produces robust and dose-dependent reductions in hepatic fat and serum alanine aminotransferase in patients with fibrotic NASH after 12 weeks of therapy: FLIGHT-FXR Part C interim results. Digestive and Liver Disease. 2020;52:e38.
Patel K, Harrison SA, Elkhashab M, et al. Cilofexor, a nonsteroidalFXRAgonist, in patients with noncirrhotic NASH: a Phase 2 randomized controlled trial. Hepatology. 2020;72:58-71.
Vlad R, Mary R, Brent T, et al. EDP-305, a non-bile acid farnesoid X receptor (FXR) agonist, showed statistically significant improvements in liver biochemistry and hepatic steatosis in the phase 2a ARGON-1 study. J Hepatol. 2020;73:S56.
Chianelli D, Rucker PV, Roland J, et al. Nidufexor (LMB763), a novel FXR modulator for the treatment of nonalcoholic steatohepatitis. J Med Chem. 2020;63:3868-3880.
Leite NC, Viegas BB, Villela-Nogueira CA, et al. Efficacy of diacerein in reducing liver steatosis and fibrosis in patients with type 2 diabetes and non-alcoholic fatty liver disease: a randomized, placebo-controlled trial. Diabetes Obes Metab. 2019;21:1266-1270.
McPherson S, Wilkinson N, Tiniakos D, et al. A randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis. PLoS One. 2017;12:e0175717.
Garcia-Tsao G, Fuchs M, Shiffman M, et al. Emricasan (IDN-6556) lowers portal pressure in patients with compensated cirrhosis and severe portal hypertension. Hepatology. 2019;69:717-728.
Garcia-Tsao G, Bosch J, Kayali Z, et al. Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension. J Hepatol. 2020;72(5):885-895.
Harrison SA, Goodman Z, Jabbar A, et al. A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis. J Hepatol. 2020;72(5):816-827.
Cusi K, Orsak B, Bril F, et al. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial. Ann Intern Med. 2016;165:305-315.
Interim analysis of RESOLVE-IT phase 3 trial of elafibranor in adults with NASH and fibrosis. https://ir.genfit.com/news-releases/news-release-details/genfit-announces-results-interim-analysis-resolve-it-phase-3. Accessed July 2020.
Presentation-NATIVE-phase-IIb-topline-results. https://inventivapharma.com/wp-content/uploads/2020/06/Presentation-NATIVE-Phase-IIb-Topline-Results-16-06-20.pdf. Accessed July 2020.
GS. A phase 2, prospective, multicenter, double- blind, randomized study of sarogliazar magnesium 1 mg, 2 mg or 4 mg versus placebo in patients with NAFLD and/or NASH ( eviden ce IV). Hepatology. 2019;70.
Alkhouri N, Lawitz E, Noureddin M, et al. GS-0976 (Firsocostat): an investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH). Expert Opin Investig Drugs. 2020;29:135-141.
Amin N, Carvajal-Gonzalez S, Aggarwal N, et al. PF-05221304 (PF'1304), a liver-targeted acetyl-coa carboxylase inhibitor (ACCI), IN adults with nonalcoholic fatty liver disease (NAFLD) demonstrates robust reductions in liver fat and alt - phase 2a dose-ranging study. Hepatology. 2019;70:21A-A22.
Ratziu V, Sanyal A, Harrison SA, et al. Cenicriviroc treatment for adults with nonalcoholic steatohepatitis and fibrosis: final analysis of the phase 2b CENTAUR study. Hepatology. 2020;72(3):892-905.
Harrison SA, Bashir MR, Guy CD, et al. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2019;394:2012-2024.
Chalasani N, Abdelmalek MF, Garcia-Tsao G, et al. Effects of belapectin, an inhibitor of galectin-3, in patients with nonalcoholic steatohepatitis with cirrhosis and portal hypertension. Gastroenterology. 2020;158:1334.
Harrison SA, Abdelmalek MF, Caldwell S, et al. Simtuzumab Is INEFFECTIVE FOR PATIENTS WITH BRIDGING FIBROSIS OR COMPENSATED CIRRHOSIS CAUSED BY NONALCOHOLIC STEATOHEPATITIS. Gastroenterology. 2018;155:1140-1153.
Results from phase 2a NASH trial with PXL770. https://www.poxelpharma.com/en_us/news-media/press-releases/detail/164/poxel-announces-positive-results-from-phase-2a-nash-trial. Accessed November 2020.
Scorletti E, Bhatia L, McCormick KG, et al. Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: results from the Welcome* study. Hepatology. 2014;60:1211-1221.
Vilar-Gomez E, Vuppalanchi R, Gawrieh S, et al. Vitamin E improves transplant-free survival and hepatic decompensation among patients with nonalcoholic steatohepatitis and advanced fibrosis. Hepatology. 2020;71:495-509.
Wicklow B, Wittmeier K, t’ Jong GW, et al. Proposed trial: safety and efficacy of resveratrol for the treatment of non-alcoholic fatty liver disease (NAFLD) and associated insulin resistance in adolescents who are overweight or obese adolescents-rationale and protocol. Biochem Cell Biol. 2015;93:522.
Fernández-Ramos D, Lopitz-Otsoa F, Delacruz-Villar L, et al. Arachidyl amido cholanoic acid improves liver glucose and lipid homeostasis in nonalcoholic steatohepatitis via AMPK and mTOR regulation. World J Gastroenterol. 2020;26:5101-5117.
Phase 2a BALANCED study in NASH patients. https://ir.akerotx.com/news-releases/news-release-details/akero-announces-strongly-positive-histological-data-across-all. Accessed July 2020.
Harrison SA, Neff G, Guy CD, et al. Final analysis of a 24-week, randomized, double-blind, placebo-controlled, multicenter study of aldafermin (NGM282) in patients with nonalcoholic steatohepatitis. Hepatology. 2020;72:55A-A56.
Armstrong MJ, Gaunt P, Aithal GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387:679-690.
Nahra R, Wang T, Oscarsson J, et al. Effects of cotadutide (MEDI0382) on biomarkers of nonalcoholic steatohepatitis (NASH) in overweight or obese subjects with type 2 diabetes mellitus (T2DM): a 26-week analysis of a randomized phase 2b study. Hepatology. 2019;70:24A-A25.
Newsome PN, Buchholtz K, Cusi K, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med. 2020;384(12):1113-1124.
Harrison SA, Alkhouri N, Davison BA, et al. Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase IIb study. J Hepatol. 2020;72:613-626.
Loomba R, Noureddin M, Kowdley KV, et al. Combination therapies including cilofexor and firsocostat for bridging fibrosis and cirrhosis due to NASH. Hepatology. 2020.
Gilead. Results from a Phase II proof-of-concept trial evaluating combinations of Novo Nordisk’s semaglutide with Gilead’s cilofexor and/or firsocostat in participants with non-alcoholic steatohepatitis (NASH). https://www.gilead.com/news-and-press/press-room/press-releases/2020/11/gilead-and-novo-nordisk-present-new-data-from-proof-of-concept-trial-in-nash. Accessed November 2020.
Loomba R, Lawitz E, Mantry PS, et al. The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: a randomized, phase 2 trial. Hepatology. 2018;67:549-559.
Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362:1675-1685.
Harrison SA, Manghi FP, Smith WB, et al. LIK066 (licogliflozin), an SGLT1/2 inhibitor, robustly decreases alt and improves markers of hepatic and metabolic health in patients with non-alcoholic fatty liver disease: interim analysis of a 12-week, randomized, placebo-controlled, phase 2a study. Hepatology. 2019;70:1482A-A1483.
Harrison SA, Wai-Sun Wong V, Okanoue T, et al. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: results from randomized Ph III STELLAR trials. J Hepatol. 2020.